Department of Histopathology, National Liver Institute in Egypt, Menoufia University, Shibin el Kom, Egypt.
Cancer Research UCC, Western Gateway Building, University College Cork, Cork, Ireland.
BMC Cancer. 2022 Aug 20;22(1):908. doi: 10.1186/s12885-022-09981-8.
Less than 20 % of patients with resectable oesophageal adenocarcinoma obtain a pathological response following neoadjuvant chemotherapy. Studies using oesophageal cancer cell lines have shown that drug sensitive tumour cells undergo apoptosis in response to drug treatment, whereas resistant cells induce autophagy and can recover following withdrawal of drug. In this study, we evaluated markers of apoptosis (active/cleaved caspase-3) and autophagy (LC3B) to establish whether these markers are useful prognostic indicators following neoadjuvant therapy.
Oesophageal adenocarcinoma tumour tissue from the Northern Ireland Biobank at Queens University Belfast was examined retrospectively. Tumours from 144 patients treated with platinum-based neoadjuvant chemotherapy followed by surgical resection were assembled into tissue microarrays prior to immunohistochemical analysis. Kaplan-Meier survival curves and log-rank tests were used to assess the impact of cleaved caspase-3 and LC3B expression on survival. Cox regression was used to examine association with clinical risk factors.
High levels of cleaved caspase-3 were found in 14.6 % of patients and this correlated with a significantly better overall survival (p = 0.03). 38.9 % of patients had high cytoplasmic LC3B expression, which correlated with poor overall survival (p = 0.041). In addition, a distinct globular pattern of LC3B expression was identified in 40.3 % of patients and was also predictive of overall survival (p < 0.001). LC3B globular structures are also associated with tumour recurrence (p = 0.014). When these markers were assessed in combination, it was found that patients who showed low/negative cleaved caspase-3 staining and high/positive staining for both patterns of LC3B had the worst overall survival (p < 0.001). Multi-variate analysis also indicated that this marker combination was an independent predictor of poor prognosis (p = 0.008; HR = 0.046, 95% CI = (0.005-0.443).
The expression of cleaved caspase-3 and specific LC3B staining patterns are associated with overall survival following neoadjuvant treatment. The combination of these markers is an independent indicator of outcome in neoadjuvant chemotherapy treated oesophageal adenocarcinoma.
在可切除的食管腺癌患者中,接受新辅助化疗后,只有不到 20%的患者获得病理缓解。使用食管癌细胞系的研究表明,药物敏感的肿瘤细胞在药物治疗下会发生细胞凋亡,而耐药细胞则会诱导自噬,并在药物撤出后恢复。在这项研究中,我们评估了细胞凋亡(活性/cleaved caspase-3)和自噬(LC3B)的标志物,以确定这些标志物在新辅助治疗后是否是有用的预后指标。
回顾性分析了贝尔法斯特女王大学北爱尔兰生物库的食管腺癌肿瘤组织。将 144 例接受铂类新辅助化疗后行手术切除的患者的肿瘤组织制成组织微阵列,然后进行免疫组织化学分析。Kaplan-Meier 生存曲线和对数秩检验用于评估 cleaved caspase-3 和 LC3B 表达对生存的影响。Cox 回归用于检查与临床危险因素的关联。
14.6%的患者cleaved caspase-3 水平较高,其总体生存率显著提高(p = 0.03)。38.9%的患者细胞质 LC3B 表达较高,与总体生存率差相关(p = 0.041)。此外,在 40.3%的患者中还发现了明显的 LC3B 表达的球形模式,这也与总体生存率相关(p < 0.001)。LC3B 球形结构也与肿瘤复发相关(p = 0.014)。当这些标志物联合评估时,发现 cleaved caspase-3 染色低/阴性和 LC3B 两种模式均高/阳性的患者总体生存率最差(p < 0.001)。多变量分析还表明,这种标志物组合是预后不良的独立预测因子(p = 0.008;HR = 0.046,95%CI = (0.005-0.443))。
cleaved caspase-3 的表达和特定的 LC3B 染色模式与新辅助治疗后的总体生存率相关。这些标志物的联合是新辅助化疗治疗食管腺癌的独立预后指标。